HBM Holdings Limited
Research HBM Holdings Limited (2142.HK) on Bullrun: market cap HKD 8.57B, P/E 12.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2142.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 8.57B
- P/E12.1
- Financial periodFY2025
- RevenueUSD 157.98M
- Revenue growth314.6%
- Net incomeUSD 91.33M
- Free cash flowUSD 69.58M
- Gross margin94.5%
Valuation Snapshot
latest market cap is HKD 8.57B; P/E is 12.1.
Peer valuation comparison
Latest P/E is 12.06x versus a Healthcare sector median of 21.69x (44.4% below).
Latest P/E is 12.06x versus a China median of 16.26x (25.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 157.98M | USD 91.33M | USD 69.58M | 94.5% | 0.12 | USD 401.90M | USD 81.77M | USD 367.13M |
| FY2024 | USD 38.10M | USD 2.78M | USD 30.44M | 88.2% | 0 | USD 165.94M | USD 61.34M | USD 124.45M |
| FY2023 | USD 89.50M | USD 22.80M | -USD 21.60M | 97.7% | 0.03 | USD 140.32M | USD 66.01M | USD 119.99M |
| FY2022 | USD 40.66M | -USD 137.22M | -USD 118.40M | 99.7% | -0.19 | USD 171.71M | USD 90.93M | USD 92.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 8.57B | 12.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About HBM Holdings Limited
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HBM Holdings Limited's market cap?
HBM Holdings Limited's market capitalization is HKD 8.57B.
What is HBM Holdings Limited's P/E ratio?
HBM Holdings Limited's price-to-earnings (P/E) ratio is 12.1.
What does HBM Holdings Limited do?
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats.